Symproic® (naldemedine) – New drug approval
March 24, 2017 – Shionogi and Purdue Pharma announced the FDA approval of Symproic (naldemedine) for the treatment of opioid-induced constipation (OIC) in adult patients with chronic non-cancer pain.
Download PDF
